Clinical Trial Update: A Bioequivalence Study of PP3M in Patients With Schizophrenia [NA]

View source ↗

Summary

A clinical trial update describing a bioequivalence study of PP3M in patients with schizophrenia, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• PP3M (paliperidone palmitate 3-month formulation)

Snippet

Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Conditions: Schizophrenia | NA | Status: RECRUITING